OraSure Technologies, Inc..
OSUR.US | Manufacture of medical and dental instruments and supplies
OraSure Technologies, Inc. develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company offers molecular collection devices, such as Oragene Dx and OMNIgene Dx product lines for collecting and stabil...Show More
Better Health for All
20
OraSure's core business, including diagnostic products for HIV, HCV, COVID-19, syphilis, Ebola, substance use, and genomics, delivers exceptional health benefits by enabling early detection and linkage to care, indicating that the entire business is devoted to health improvement.
1
The company offers free HIV and HCV screening programs since 2016 and 2013, respectively,
2
and provides subsidized OraQuick HIV Self-Tests in 50 developing countries with $20 million in funding from the Gates Foundation,
3
demonstrating products priced below cost in low-income regions. OraSure targets vulnerable populations such as immigrants, the homeless, and LGBTQIA+ communities, reaching 95-97% of these groups through community-based testing in various settings.
4
The company has ethical marketing policies ensuring claims are data-supported and compliant with regulations.
5
OraSure is investing in innovation by combining commercial and innovation teams and developing new diagnostic tests to support PrEP adherence, allocating 10-11% of its R&D budget to health improvement.
6
Cybersecurity and data protection policies follow the NIST framework,
7
and data from a multi-site study was collected and stored securely with anonymized participant IDs.
8
During the COVID-19 pandemic, OraSure increased manufacturing and testing of its Inteliswab COVID-19 rapid test,
9
demonstrating significant contributions during emergencies. The company emphasizes early detection and prevention of HIV/HCV through linkage to PrEP and early intervention strategies, with 11-12% of its health-related expenditure focused on prevention.
10
OraSure provides education about HIV/HCV, stigma reduction, and care pathways during testing, with extensive reach and significant measurable impact.
11
Clinical trials for the OraQuick HIV Self-Test were conducted with Health Canada-approved Investigational Testing Authorization and Research Ethics Boards approval, with informed consent from participants.
12
Fair Money & Economic Opportunity
0
OraSure Technologies, Inc. develops, manufactures, and markets diagnostic products and specimen collection devices. The company's core business does not involve lending, insuring, moving, or storing money, nor does it offer consumer credit products or financial services. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives (loan/insurance book), data accessibility (customer finance data), fair lending compliance, wealth building outcome, profit reinvestment (community finance), financial literacy initiatives, debt burden ratio, geographic inclusion (financial service access points), and product simplicity (financial products), are not applicable to its operations. The rubric assigns a score of 0 for these KPIs when the firm does not offer relevant financial services or products.
Fair Pay & Worker Respect
0
No evidence available to assess OraSure Technologies, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess OraSure Technologies, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
The company has a formal whistleblower policy that allows complaints to be made directly to the General Counsel or on a confidential, anonymous basis, covering a wide range of issues including accounting matters, financial reporting, and fraud against stockholders.
1
However, there is no evidence of independent investigation processes or resolution times. The company has a compensation recoupment (clawback) policy, allowing recovery of excess executive compensation if financial statements are restated.
2
In 2023, the company successfully completed 15 external assessments of its quality system, and its quality system was evaluated by regulatory agencies and certifying bodies including FDA, MDSAP, and ISO with positive results.
3
The board has 7 members, with three females and four males, and an average tenure of 3.5-3.9 years.
4
All standing committees (Audit, Compensation, Nominating & Corporate Governance) are fully independent, and there are no compensation committee interlocks or related-party transactions requiring proxy disclosure since January 1, 2024.
5
The company has an Anti-Corruption Policy, but details on its enforcement, training frequency, or effectiveness metrics are not provided.
6
The company worked with a third-party consultant for a follow-up study on Scope 1 and 2 GHG emissions in 2023, aligning with The Greenhouse Gas Protocol, and its quality system's health was evaluated by regulatory agencies and certifying bodies.
7
Kind to Animals
0
No relevant data was found in the provided article to assess OraSure Technologies, Inc. against the 'Kind to Animals' ethical value.
1
The article discusses rapid diagnostic tests and sample collection solutions but does not contain any specific information regarding animal testing, cruelty-free certifications, animal-derived ingredients, humane practices, or wildlife conservation efforts.
2
No War, No Weapons
0
OraSure Technologies, Inc. was awarded a $109 million contract from the U.S. Department of Defense in October 2021.
1
However, this contract is explicitly for COVID-19 testing, indicating it is not an arms or defense contract.
2
The company's core business involves diagnostic products and specimen collection devices, which are civilian in nature. There is no evidence of revenue derived from arms or defense contracts.
3
For all other KPIs, the provided articles explicitly state that no data is presented or that the information is not applicable.
Planet-Friendly Business
-70
OraSure Technologies does not have third-party validated near or long-term GHG reduction targets aligned with holding warming to 1.5°C.
1
The company purchased 21,754,453 kWh of carbon-free energy for its corporate headquarters and some Bethlehem-based manufacturing sites,
2
but a percentage of total operational energy from renewables is not provided. Total water usage was 9,631 cubic meters in 2023,
3
with a 2024 revenue of $328 million,
4
resulting in approximately 29.36 m³ per $1M revenue. The waste diversion rate was 42.3% in 2023.
5
The company purchased 232 tons of carbon offsets against corporate air travel,
6
but the quality rating is not specified. New packaging for the OraQuick® HIV Self-Test is expected to reduce paper and plastic usage by 1,500 tons and 450 tons annually, respectively,
7
and InteliSwab® packaging changes resulted in a ~95% lower CO2 from shifting to ocean from air freight.
8
The company has not declared a net-zero target year
9
and does not provide TCFD-aligned disclosures.
10
Respect for Cultures & Communities
0
No relevant data was found in the provided articles to assess OSUR.US against the 'Respect for Cultures & Communities' value. Both articles returned 404 errors, indicating no information was available for extraction or summarization.
1
Safe & Smart Tech
-30
OraSure Technologies experienced an unauthorized access incident around March 27, 2024, where an unauthorized third party gained access to certain information systems and took files.
1
The company notified the SEC on April 12, 2024, and publicly disclosed the incident on April 17, 2024.
2
The extent of sensitive information accessed and the number of affected users are still under investigation.
3
The company's privacy policy outlines user rights to access, rectify, erase, restrict, object to, and transfer their data.
4
It also states that data is retained only as long as necessary for its original or compatible purpose.
5
The privacy policy mentions compliance with GDPR, effective May 25, 2018.
6
However, the company is currently assessing any required regulatory and legal notifications related to the recent cybersecurity incident, and no specific regulatory actions, violations, or fines have been mentioned.
7
Zero Waste & Sustainable Products
-10
OraSure Technologies has implemented numerous waste reduction initiatives with measurable results. These include an annual reduction of 1,500 tons of paper and 450 tons of plastic for the OraQuick® HIV Self-Test packaging.
1
In 2022, the company achieved approximately 230 metric tons of plastic reduction and 8,300 metric tons of paper reduction.
2
A packaging reduction pilot project for the InteliSwab® COVID-19 Rapid Test resulted in a 450g lighter shipper, 25g lighter unit box, and 15g lighter IFU/Reference Card.
3
Manufacturing scrap rates were significantly reduced from 30% to less than 1%.
4
Additionally, pallet efficiency improved by approximately 750 metric tons, and a projected 10,000 metric ton reduction was achieved by shifting from air to ocean freight.
5
The company has not reported any waste disposal violations in the past three years.
6
No specific details regarding hazardous waste management beyond general compliance are provided.